Benzinga's Top #PreMarket Losers

Regado Biosciences RGDO dropped 42.31% to $3.90 in pre-market trading following the announcement of halt of patient enrollment in REGULATE-PCI trial. Wedbush downgraded Regado Biosciences from Outperform to Underperform. BIND Therapeutics BIND shares declined 12.66% to $11.25 in pre-market trading after the company reported the closing of collaboration deal with Amgen AMGN. Real Goods Solar RGSE fell 4.83% to $2.76 in pre-market trading as the company priced 2.92 million units at $2.40 per unit. SYNNEX SNX dipped 1.28% to $72.98 in pre-market trading after the company issued a downbeat outlook for the third quarter. It expected adjusted earnings of $1.45 to $1.50 per share on revenue of $3.3 billion to $3.4 billion. Analysts were projecting earnings of $1.53 per share on revenue of $3.29 billion.